Eupraxia Pharmaceuticals Stock Price To Book
| EPRXFDelisted Stock | USD 2.79 0.04 1.45% |
Eupraxia Pharmaceuticals fundamentals help investors to digest information that contributes to Eupraxia Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eupraxia Pink Sheet. The fundamental analysis module provides a way to measure Eupraxia Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eupraxia Pharmaceuticals pink sheet.
Eupraxia |
Eupraxia Pharmaceuticals Company Price To Book Analysis
Eupraxia Pharmaceuticals' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Eupraxia Pharmaceuticals Price To Book | 3.89 X |
Most of Eupraxia Pharmaceuticals' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eupraxia Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
CompetitionBased on the latest financial disclosure, Eupraxia Pharmaceuticals has a Price To Book of 3.8908 times. This is 84.85% lower than that of the Healthcare sector and 35.58% lower than that of the Biotechnology industry. The price to book for all United States stocks is 59.09% higher than that of the company.
Eupraxia Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eupraxia Pharmaceuticals' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Eupraxia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eupraxia Pharmaceuticals by comparing valuation metrics of similar companies.Eupraxia Pharmaceuticals is currently under evaluation in price to book category among its peers.
Eupraxia Fundamentals
| Return On Equity | -0.89 | |||
| Return On Asset | -0.33 | |||
| Current Valuation | 43.78 M | |||
| Shares Outstanding | 21.39 M | |||
| Shares Owned By Insiders | 12.40 % | |||
| Shares Owned By Institutions | 20.24 % | |||
| Price To Book | 3.89 X | |||
| EBITDA | (21.96 M) | |||
| Net Income | (22.99 M) | |||
| Cash And Equivalents | 35.46 M | |||
| Cash Per Share | 1.66 X | |||
| Total Debt | 9.26 M | |||
| Debt To Equity | 0.42 % | |||
| Current Ratio | 10.13 X | |||
| Book Value Per Share | 0.95 X | |||
| Cash Flow From Operations | (14.64 M) | |||
| Earnings Per Share | (0.98) X | |||
| Number Of Employees | 19 | |||
| Market Capitalization | 78.89 M | |||
| Total Asset | 31.22 M | |||
| Z Score | 4.8 | |||
| Net Asset | 31.22 M |
About Eupraxia Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eupraxia Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eupraxia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eupraxia Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Eupraxia Pink Sheet
If you are still planning to invest in Eupraxia Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eupraxia Pharmaceuticals' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |